Developer docs
API playgroundTry for free, no card

Search company profiles

Lumiata

Full company profile

uuid0000xv8

Namestring
Lumiata
Websiteurl
lumiata.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Lumiata is a private healthcare technology company headquartered in McLean, Virginia, founded in 2013, that operates a value-based care platform targeting kidney and heart disease management. The company describes itself as driving "predictability and precision at scale" to help healthcare organizations reduce risk and manage costs using AI-enabled decision support. It serves three primary stakeholder groups: patients managing chronic kidney and heart conditions who receive clinical, emotional, and social support; healthcare providers including nephrologists, cardiologists, and care teams seeking to extend their capabilities; and health insurance plans seeking to reduce hospitalization costs and improve member outcomes.

The core product is the proprietary RenalIQ technology platform, which supports intelligent decision-making across the kidney and heart care continuum and integrates with health plan and provider workflows. Lumiata complements this technology with local, hands-on health support teams that deliver individualized clinical, emotional, and social interventions, and offers a self-serve patient portal for direct member engagement. The company holds NCQA Health Equity Accreditation across Case Management, Population Health Program, and Health Equity, as well as HITRUST CSF certification, which serve as procurement prerequisites for many enterprise health plan customers. Revenue is generated through value-based contracts with health plans, where pricing is not publicly disclosed but contracts are structured around shared financial risk and outcome-based economics rather than per-seat licensing. The go-to-market is primarily direct enterprise sales to health plans and provider systems, supplemented by content marketing, webinars, and social media presence for top-of-funnel awareness. Lumiata has raised approximately $45 million in disclosed equity funding across six rounds from 2014 through January 2021, with investors including Khosla Ventures, Intel Capital, Allegis Capital, Defy.vc, and strategic backers such as Blue Cross Blue Shield Association and Sandbox Industries. Leadership includes Dilawar Syed as President & CEO, with a Senior Director of Data Science and a Director of Customer Success on the team, indicating a composition weighted toward enterprise operations and technical depth.

Short descriptiontext

Lumiata is a McLean, Virginia-based healthcare AI company that operates a value-based kidney and heart care management platform, serving health plans, providers, and patients through risk-sharing contracts and a proprietary decision-support technology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare AI analytics, predictive risk modeling, value-based care, population health management, clinical analytics
Industry4 codes
PRIMARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAFAC
Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics
NAICS code3 codes
  • Computer Systems Design and Related Services54151
  • Other Scientific and Technical Consulting Services541690
  • Social Assistance624
SIC code2 codes
  • Services-Health Services8000
  • Services-Computer Integrated Systems Design7373
Product category
Healthcare AI Analytics
Social media profiles2 records
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Lumiata provides AI-powered analytics and decision-support technology for healthcare organizations to predict risk, manage costs, and improve outcomes at scale. The company operates a value-based care technology platform centered on its proprietary RenalIQ Technology Platform, which enables intelligent decision-making for kidney, heart, and broader population health management through integration and interoperability with healthcare data systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Significantly reduced hospital admissions
+2 more records
Product and service1 record
1RenalIQ Technology Platform
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Value-based kidney care provider formed from Fresenius, Cricket Health, and InterWell — directly competes in the same risk-bearing kidney care contracts with health plans.

TypeDirect peer
Description

In-home kidney and polychronic care provider operating under value-based contracts with major health plans, using proprietary technology and local clinical teams — closely aligned with Lumiata's care-and-tech hybrid.

TypeDirect peer
Description

Kidney care company combining predictive analytics with multidisciplinary care teams under risk-bearing arrangements with payers — directly comparable AI-plus-care-team model.

TypeDirect peer
Description

Value-based kidney and heart care provider working with health plans through local care teams and proprietary technology — the most direct comparable to Lumiata's stated model in the kidney/cardiac value-based care category.

TypeEmerging player
Description

Healthcare-specific AI/ML platform for predictive risk and outcomes modeling — comparable AI technology layer, though Lumiata combines this with delivered clinical services.

TypeBroad incumbent
Description

Health and community care technology and analytics company serving payers, providers, and care managers — broader incumbent with overlapping care management and population health capabilities.

TypeEmerging player
Description

AI-driven healthcare automation platform targeting payers and providers with workflow and administrative intelligence — adjacent AI-for-healthcare play with overlapping buyer personas.

TypeBroad incumbent
Description

Healthcare data and analytics platform serving health systems and payers with population health and outcomes improvement capabilities — broader incumbent with overlapping data/analytics functionality.

TypeDirect peer
Description

Value-based kidney care company partnering with health plans and providers to deliver CKD/ESRD care, including home dialysis and transplant support — directly comparable services and customer base.

TypeBroad incumbent
Description

Value-based care enablement platform and services for health plans and providers, including population health and care management — broader incumbent serving similar payer/provider customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lumiata

Healthcare AI Analyticslumiata.com

Lumiata is a McLean, Virginia-based healthcare AI company that operates a value-based kidney and heart care management platform, serving health plans, providers, and patients through risk-sharing contracts and a proprietary decision-support technology.

What Lumiata does

Lumiata is a private healthcare technology company headquartered in McLean, Virginia, founded in 2013, that operates a value-based care platform targeting kidney and heart disease management. The company describes itself as driving "predictability and precision at scale" to help healthcare organizations reduce risk and manage costs using AI-enabled decision support. It serves three primary stakeholder groups: patients managing chronic kidney and heart conditions who receive clinical, emotional, and social support; healthcare providers including nephrologists, cardiologists, and care teams seeking to extend their capabilities; and health insurance plans seeking to reduce hospitalization costs and improve member outcomes.

The core product is the proprietary RenalIQ technology platform, which supports intelligent decision-making across the kidney and heart care continuum and integrates with health plan and provider workflows. Lumiata complements this technology with local, hands-on health support teams that deliver individualized clinical, emotional, and social interventions, and offers a self-serve patient portal for direct member engagement. The company holds NCQA Health Equity Accreditation across Case Management, Population Health Program, and Health Equity, as well as HITRUST CSF certification, which serve as procurement prerequisites for many enterprise health plan customers. Revenue is generated through value-based contracts with health plans, where pricing is not publicly disclosed but contracts are structured around shared financial risk and outcome-based economics rather than per-seat licensing. The go-to-market is primarily direct enterprise sales to health plans and provider systems, supplemented by content marketing, webinars, and social media presence for top-of-funnel awareness. Lumiata has raised approximately $45 million in disclosed equity funding across six rounds from 2014 through January 2021, with investors including Khosla Ventures, Intel Capital, Allegis Capital, Defy.vc, and strategic backers such as Blue Cross Blue Shield Association and Sandbox Industries. Leadership includes Dilawar Syed as President & CEO, with a Senior Director of Data Science and a Director of Customer Success on the team, indicating a composition weighted toward enterprise operations and technical depth.

Lumiata firmographics

Firmographics
Name
Lumiata
Website
https://lumiata.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Lumiata is a McLean, Virginia-based healthcare AI company that operates a value-based kidney and heart care management platform, serving health plans, providers, and patients through risk-sharing contracts and a proprietary decision-support technology.
Ownership category
akta.pro rank

Lumiata industry classification

Industry
Product category
Healthcare AI Analytics
NAICS
Computer Systems Design and Related Services (54151), Other Scientific and Technical Consulting Services (541690), Social Assistance (624)
SIC
Services-Health Services (8000), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAFAC
Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics

Keywords

  • Healthcare AI analytics
  • Predictive risk modeling
  • Value-based care
  • Population health management
  • Clinical analytics

Where Lumiata is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Lumiata business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels3 records

Marketing channels4 records

Lumiata product offering

Product offering

Core offering

Lumiata provides AI-powered analytics and decision-support technology for healthcare organizations to predict risk, manage costs, and improve outcomes at scale. The company operates a value-based care technology platform centered on its proprietary RenalIQ Technology Platform, which enables intelligent decision-making for kidney, heart, and broader population health management through integration and interoperability with healthcare data systems.

Differentiator

Problem solved

Functional benefit

Products and services

  • RenalIQ Technology Platform

Quantifiable outcome

  • Significantly reduced hospital admissions
  • +2 more outcomes

Companies that use Lumiata

Customer profile

Segments3 records

Ideal customer profiles1 record

Lumiata technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Lumiata partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Lumiata competitors and assessment

Company assessment

Direct peers

  • InterWell Health: Value-based kidney care provider formed from Fresenius, Cricket Health, and InterWell — directly competes in the same risk-bearing kidney care contracts with health plans.
  • Monogram Health: In-home kidney and polychronic care provider operating under value-based contracts with major health plans, using proprietary technology and local clinical teams — closely aligned with Lumiata's care-and-tech hybrid.
  • Cricket Health: Kidney care company combining predictive analytics with multidisciplinary care teams under risk-bearing arrangements with payers — directly comparable AI-plus-care-team model.
  • Somatus: Value-based kidney and heart care provider working with health plans through local care teams and proprietary technology — the most direct comparable to Lumiata's stated model in the kidney/cardiac value-based care category.
  • Strive Health: Value-based kidney care company partnering with health plans and providers to deliver CKD/ESRD care, including home dialysis and transplant support — directly comparable services and customer base.

Emerging players

  • ClosedLoop.ai: Healthcare-specific AI/ML platform for predictive risk and outcomes modeling — comparable AI technology layer, though Lumiata combines this with delivered clinical services.
  • Olive AI: AI-driven healthcare automation platform targeting payers and providers with workflow and administrative intelligence — adjacent AI-for-healthcare play with overlapping buyer personas.

Broad incumbents

  • WellSky: Health and community care technology and analytics company serving payers, providers, and care managers — broader incumbent with overlapping care management and population health capabilities.
  • Health Catalyst: Healthcare data and analytics platform serving health systems and payers with population health and outcomes improvement capabilities — broader incumbent with overlapping data/analytics functionality.
  • Lumeris: Value-based care enablement platform and services for health plans and providers, including population health and care management — broader incumbent serving similar payer/provider customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Lumiata social profiles

Digital presence

Lumiata financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lumiata leadership team

Management profile

Number of profiles

Profiles3 records

Lumiata funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lumiata M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumiata

What does Lumiata do?

Lumiata provides AI-powered analytics and decision-support technology for healthcare organizations to predict risk, manage costs, and improve outcomes at scale. The company operates a value-based care technology platform centered on its proprietary RenalIQ Technology Platform, which enables intelligent decision-making for kidney, heart, and broader population health management through integration and interoperability with healthcare data systems.

Is Lumiata a public or private company?

Lumiata is a private company. It is classified as venture growth investor backed and is currently operating.

When was Lumiata founded?

Lumiata was founded in 2013. It employs 1 to 10 people.

Where is Lumiata based?

Lumiata is headquartered in San Mateo, United States, in the North America region.

Who are Lumiata's main competitors?

Direct peers on record are InterWell Health, Monogram Health, Cricket Health, Somatus and Strive Health. Emerging players are ClosedLoop.ai and Olive AI. Broad incumbents are WellSky, Health Catalyst and Lumeris.

Does Lumiata have an API?

No public API is recorded for Lumiata.

What industry is Lumiata in?

Lumiata's product category is Healthcare AI Analytics. Its primary akta.pro industry code is HLACAFAO, Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways), with a secondary code of HLALAFAC, Kidney & Dialysis Remote Care (CKD/ESRD monitoring, home dialysis support). Its NAICS code is 54151 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SomatusSomatus Enhances Predictive Capabilities and Risk Accuracy Through Acquisition of LumiataSomatus has acquired strategic assets from Lumiata to enhance its predictive capabilities and improve its ability to identify chronic kidney disease patients earlier. This acquisition aims to reduce costs for healthcare providers and health plans while addressing healthcare disparities. By integrating Lumiata's AI-driven analytics, Somatus intends to advance patient care outcomes in the kidney care industry.Business Wire BlogSomatus Enhances Predictive Capabilities and Risk Accuracy Through Acquisition of LumiataSomatus acquired strategic assets from Lumiata, a healthcare AI platform, to enhance predictive analytics for identifying high-cost claimants and disease progression. The acquisition aims to reduce costs for provider and health plan partners and address healthcare disparities. Lumiata's CEO will join Somatus as Senior Vice President of Growth Analytics.PR NewswireLumiata Extends Data Preparation for Healthcare Customers on AWS and Azure in Partnership with Ascend.ioLumiata announced a partnership with Ascend.io to provide its proprietary data preparation process to healthcare customers on AWS and Azure. The cloud-agnostic solution enables data normalization, enrichment, and tagging with Lumiata's proprietary disease codes to generate Person360 records. The partnership aims to support customers in their own virtual private cloud environments.FierceHealthcareBCBSA backs Lumiata's $14M round to boost COVID-19 risk management using AILumiata raised $14 million in a Series B round backed by Defy.vc, AllegisNL Capital, Khosla Ventures, and Blue Venture Fund. The AI platform analyzes healthcare data to predict patient risk and underwriting costs. The company plans to scale its platform and open a new office in Guadalajara.AiThorityLumiata Healthcare Underwriting Models Wins Prestigious IAAILumiata won the Deployed Application Award at IAAI-21 for its paper on AI actuarial models for health insurance pricing. The models, trained on over 12 million patients, outperformed existing pricing by 20% and identified 84% of concession opportunities. The paper will be presented at the virtual IAAI-21 conference in February 2021.AiThorityHealthcare Specific AI Platform Lumiata Raises FundingLumiata, a healthcare-specific AI platform, raised $14 million in Series B funding led by Defy.vc and AllegisNL Capital. The company will use the funds to scale its enterprise-grade AI platform and invest in customer acquisition, and plans to open a new office in Guadalajara, Mexico in 2021.PR NewswireHealthcare Specific AI Platform Lumiata Raises Series B FundingLumiata, a healthcare-specific AI platform, raised $14 million in Series B funding led by Defy.vc and AllegisNL Capital, with existing investors Khosla Ventures and Blue Venture Fund. The company will use the funds to scale its enterprise-grade AI platform and invest in customer acquisition, and plans to open a new office in Guadalajara, Mexico in 2021.VC News DailyLumiata Completes $14M Series B FinancingLumiata, a healthcare AI platform, completed $14 million in Series B funding led by Defy.vc and AllegisNL Capital, with existing investors including Khosla Ventures and Blue Venture Fund. The funding aims to enhance its predictive healthcare tools built from extensive patient data.PR NewswireLumiata Healthcare Underwriting Models Wins Prestigious IAAI Deployed Application AwardLumiata won the prestigious Deployed Application Award at the IAAI-21 conference for its paper on accurate and interpretable machine learning for transparent health insurance pricing. The company's models demonstrated 20% better performance than existing pricing models and identified 84% of concession opportunities, based on a study of over 12 million patients. Lumiata CEO stated the award validates the company's innovative approach to predictive AI for healthcare companies.PR NewswireLumiata CEO Co-Leads the Plan for Small Businesses as Part of the Silicon Valley Recovery RoundtableThe Silicon Valley Recovery Roundtable released its final report 'Building a Better Normal,' outlining over 25 policy recommendations to aid Silicon Valley's economic recovery from the COVID-19 pandemic. Lumiata CEO Dilawar Syed co-led the small business and startups focus area, helping develop recommendations for early-stage companies that have been disproportionately affected by the economic downturn. The 72-page report addresses four key areas including getting families back to work, supporting small businesses, and ensuring vulnerable residents can participate in the recovery.